Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strickler

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Nature Communications|January 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysisJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
The Lancet. Oncology|August 8, 2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2018
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeC M Parseghian, J M Loree, V K Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Investigational New Drugs|April 9, 2014
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumorsFatima Rangwala, Johanna C Bendell, Mark F Kozloff, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
NPJ Precision Oncology|May 5, 2026
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysisBinbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Nature Reviews. Clinical Oncology|July 8, 2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaperArvind Dasari, Van K Morris, Carmen J Allegra, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Nature Communications|January 12, 2026
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysisJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
The Lancet. Oncology|August 8, 2024
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Salvatore Siena, Atsuo Takashima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 22, 2018
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challengeC M Parseghian, J M Loree, V K Morris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2026
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid TumorsManish R Sharma, John Powderly, Yasutoshi Kuboki, et al.
Investigational New Drugs|April 9, 2014
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumorsFatima Rangwala, Johanna C Bendell, Mark F Kozloff, et al.
Neuro-Oncology Advances|February 23, 2023
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastomaBenedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, et al.
NPJ Precision Oncology|May 5, 2026
Survival outcomes with matched targeted therapy in advanced biliary tract cancer: a large global cohort analysisBinbin Zheng-Lin, Taro Shibuki, Heidi E Kosiorek, et al.
Cancer Cell|January 9, 2026
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC programSalvador Alonso, Kanwal Raghav, Van K Morris, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
Nature Reviews. Clinical Oncology|July 8, 2020
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaperArvind Dasari, Van K Morris, Carmen J Allegra, et al.
Pageof 10